The intracellular signalosome of PD-L1 in cancer cells

被引:221
作者
Escors, David [1 ,2 ]
Gato-Canas, Maria [1 ]
Zuazo, Miren [1 ]
Arasanz, Hugo [1 ,3 ]
Jesus Garcia-Granda, Maria [1 ]
Vera, Ruth [3 ]
Kochan, Grazyna [1 ]
机构
[1] Complejo Hosp Navarra, IdISNA, Navarrabiomed, Irunlarrea 3, Pamplona 31008, Navarra, Spain
[2] UCL, Rayne Inst, Div Infect & Immun, 5 Univ St, London WC1E 6JF, England
[3] Complejo Hosp Navarra, IdISNA, Oncol Dept, Irunlarrea 3, Pamplona 31008, Navarra, Spain
关键词
T-CELLS; B7-H1; EXPRESSION; TUMOR-CELLS; B7; FAMILY; IFN-GAMMA; PROGRAMMED CELL-DEATH-1; ACQUIRED-RESISTANCE; SIGNALING PATHWAYS; CARCINOMA PATIENTS; DOWN-MODULATION;
D O I
10.1038/s41392-018-0022-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Programmed cell death-1 ligand-1 (PD-L1) overexpression in cancer cells accelerates tumor progression. PD-L1 possesses two main pro-oncogenic functions. First, PD-L1 is a strong immunosuppressive molecule that inactivates tumor-specific T cells by binding to the inhibitory receptor PD-1. Second, PD-L1 function relies on the delivery of intrinsic intracellular signals that enhance cancer cell survival, regulate stress responses and confer resistance toward pro-apoptotic stimuli, such as interferons. Here, we review the current knowledge on intracellular signal transduction pathways regulated by PD-L1, describe its associated signalosome and discuss potential combinations of targeted therapies against the signalosome with PD-L1/PD-1 blockade therapies.
引用
收藏
页数:9
相关论文
共 113 条
[81]   Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development [J].
Powles, Thomas ;
Necchi, Andrea ;
Rosen, Galit ;
Hariharan, Subramanian ;
Apolo, Andrea B. .
CLINICAL GENITOURINARY CANCER, 2018, 16 (02) :117-129
[82]   Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma [J].
Prat, Aleix ;
Navarro, Alejandro ;
Pare, Laia ;
Reguart, Noemi ;
Galvan, Patricia ;
Pascual, Tomas ;
Martinez, Alex ;
Nuciforo, Paolo ;
Comerma, Laura ;
Alos, Llucia ;
Pardo, Nuria ;
Cedres, Susana ;
Fan, Cheng ;
Parker, Joel S. ;
Gaba, Lydia ;
Victoria, Ivan ;
Vinolas, Nuria ;
Vivancos, Ana ;
Arance, Ana ;
Felip, Enriqueta .
CANCER RESEARCH, 2017, 77 (13) :3540-3550
[83]   Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma [J].
Qi, Xinmeng ;
Jia, Bo ;
Zhao, Xue ;
Yu, Dan .
ONCOTARGETS AND THERAPY, 2017, 10 :5745-5754
[84]   Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma [J].
Ritprajak, Patcharee ;
Azuma, Miyuki .
ORAL ONCOLOGY, 2015, 51 (03) :221-228
[85]   Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [J].
Rittmeyer, Achim ;
Barlesi, Fabrice ;
Waterkamp, Daniel ;
Park, Keunchil ;
Ciardiello, Fortunato ;
von Pawel, Joachim ;
Gadgeel, Shirish M. ;
Hida, Toyoaki ;
Kowalski, Dariusz M. ;
Dols, Manuel Cobo ;
Cortinovis, Diego L. ;
Leach, Joseph ;
Polikoff, Jonathan ;
Barrios, Carlos ;
Kabbinavar, Fairooz ;
Frontera, Osvaldo Aren ;
De Marinis, Filippo ;
Turna, Hande ;
Lee, Jong-Seok ;
Ballinger, Marcus ;
Kowanetz, Marcin ;
He, Pei ;
Chen, Daniel S. ;
Sandler, Alan ;
Gandara, David R. .
LANCET, 2017, 389 (10066) :255-265
[86]   Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer [J].
Rizvi, Naiyer A. ;
Hellmann, Matthew D. ;
Snyder, Alexandra ;
Kvistborg, Pia ;
Makarov, Vladimir ;
Havel, Jonathan J. ;
Lee, William ;
Yuan, Jianda ;
Wong, Phillip ;
Ho, Teresa S. ;
Miller, Martin L. ;
Rekhtman, Natasha ;
Moreira, Andre L. ;
Ibrahim, Fawzia ;
Bruggeman, Cameron ;
Gasmi, Billel ;
Zappasodi, Roberta ;
Maeda, Yuka ;
Sander, Chris ;
Garon, Edward B. ;
Merghoub, Taha ;
Wolchok, Jedd D. ;
Schumacher, Ton N. ;
Chan, Timothy A. .
SCIENCE, 2015, 348 (6230) :124-128
[87]   PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma [J].
Ruf, Melanie ;
Moch, Holger ;
Schraml, Peter .
INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (02) :396-403
[88]   Targeting the ATR-CHK1 Axis in Cancer Therapy [J].
Rundle, Stuart ;
Bradbury, Alice ;
Drew, Yvette ;
Curtin, Nicola J. .
CANCERS, 2017, 9 (05)
[89]  
Sathianathen NJ, 2017, IMMUNOTARGETS THER, V6, P83, DOI 10.2147/ITT.S134850
[90]   Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy [J].
Sharma, Padmanee ;
Hu-Lieskovan, Siwen ;
Wargo, Jennifer A. ;
Ribas, Antoni .
CELL, 2017, 168 (04) :707-723